This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Cadence Pharmaceuticals, Inc. (CADX)

Q2 2012 Earnings Call

August 2, 2012, 04:30 pm ET


Ted Schroeder - President & CEO

Bill LaRue - SVP & CFO

Jim Breitmeyer - EVP & CMO

Scott Byrd - SVP & Chief Commercial Officer


Charles Duncan - JMP Securities

Richard Lau - Wedbush Securities

Imran Babar - Cowen

Michael Schmidt - Leerink Swann

Patti Bank - DISCERN Securities

Juan Sanchez - Ladenburg

Greg Fraser - Bank of America



Good afternoon and welcome to the Cadence Pharmaceuticals second quarter 2012 financial results conference call. On the call today are Ted Schroeder, President and CEO, Bill LaRue, Senior Vice President and Chief Financial Officer, Jim Breitmeyer, Executive Vice President and Chief Medical Officer, and Scott Byrd, Senior Vice President and Chief Commercial Officer.

At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the company, we will open the conference up for questions-and-answers after the management presentation.

Our first speaker is Bill LaRue. Go ahead, sir.

Bill LaRue

Thank you. Good afternoon everyone. Before we begin, I would like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Forward-looking statements include statements regarding financial guidance, expectations regarding sales and demand, formulary approval, revenue growth, expenses and the market opportunity for OFIRMEV. The status of the recalls of OFIRMEV and related investigation, our expectation that no supply shortages will result from the July 2012 recall, knowing the cost of this recall have a material impact on our financial statements and the date on which we expect to commence enrollment in our post approval pediatric clinical trial of OFIRMEV. You are cautioned not to place undue reliance on these forward-looking statements which speak only as of the day that hereof.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs